Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 89.28% is 110% above its 3-year average of -862.60%, near the high end of its 3-year range (-2765.09%–98.58%).
107.36% above its 12-month average of -1213.43%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
GROSS MARGIN
89.28%
GROSS MARGIN AVG TTM
-1213.43%
GROSS MARGIN AVG 3Y
-862.60%
GROSS MARGIN AVG 5Y
0.00%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+107.36%
CURRENT VS 3Y AVG
+110.35%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.38%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
+115.76%
vs the sector median at left
Rallybio Corporation
Market Cap
$90.64M
Gross Margin
89.28%
TTM Avg
-1213.43%
3Y Avg
-862.60%
5Y Avg
0.00%
Market Cap
$90.20M
Gross Margin
40.32%
TTM Avg
35.69%
3Y Avg
34.43%
5Y Avg
37.90%
Market Cap
$89.44M
Gross Margin
87.06%
TTM Avg
85.86%
3Y Avg
83.85%
5Y Avg
76.72%
Market Cap
$87.85M
Gross Margin
82.44%
TTM Avg
83.07%
3Y Avg
-40.55%
5Y Avg
-241.44%
Market Cap
$93.96M
Gross Margin
10.89%
TTM Avg
14.00%
3Y Avg
13.41%
5Y Avg
13.41%
Market Cap
$87.27M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Rallybio Corporation (RLYB) | $90.64M | 89.28% | -1213.43% | -862.60% | 0.00% |
| Biomea Fusion, Inc. (BMEA)vs › | $90.37M | 0.00% | 0.00% | 0.00% | 0.00% |
| ImmuCell Corporation (ICCC)vs › | $90.20M | 40.32% | 35.69% | 34.43% | 37.90% |
| Equillium, Inc. (EQ)vs › | $89.78M | 0.00% | 50.00% | 75.00% | 50.00% |
| electroCore, Inc. (ECOR)vs › | $89.44M | 87.06% | 85.86% | 83.85% | 76.72% |
| CareCloud, Inc. (CCLD)vs › | $87.96M | 46.51% | 45.81% | 42.58% | 41.06% |
| Atara Biotherapeutics, Inc. (ATRA)vs › | $87.85M | 82.44% | 83.07% | -40.55% | -241.44% |
| Park Dental Partners, Inc. Common Stock (PARK)vs › | $93.96M | 10.89% | 14.00% | 13.41% | 13.41% |
| Neumora Therapeutics, Inc. Common Stock (NMRA)vs › | $87.27M | 0.00% | 0.00% | 0.00% | 0.00% |
| Milestone Pharmaceuticals Inc. (MIST)vs › | $95.14M | 94.58% | 46.31% | 73.16% | 65.44% |
Gross Margin
89.3%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 98.58% |
| 2025-12-31 | -1546.40% |
| 2025-09-30 | -1854.25% |
| 2025-06-30 | -2765.09% |
| 2025-03-31 | -2600.47% |
| 2024-12-31 | 21.05% |
| 2024-09-30 | -2655.85% |
| 2024-06-30 | 88.63% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 0.00% |
| 2022-12-31 | 0.00% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.00% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | 0.00% |
